Mosanna Therapeutics, a Basel-based biotechnology company developing the highly differentiated small molecule MOS118 for the treatment of metabolic obstructive sleep apnea, has closed an extension of the Seed Financing Round with the investors Supermoon Capital,
Tags :Matthias Staehelin
Intel Capital, an investor in the future of compute, has invested in Unisers, a Swiss semiconductor metrology company that identifies invisible contamination-caused defects in semiconductor materials. The USD14 million seed financing round was led
Oculis Holding, a global biopharmaceutical company, purposefully driven to save sight and improve eye care, listed its shares on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp. (“EBAC”). At closing, Oculis
As we have informed here, the AMR Action Fund, the world’s largest public-private partnership investing in biotech companies that are developing antimicrobials, has invested in BioVersys, a clinical-stage company based in Basel, Switzerland. The
Anokion, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, recently closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. Founded in Switzerland and based
Norgine Ventures has provided financing of approx. EUR 10 million to Lunaphore Technologies, a privately owned Swiss company spun out from EPFL. The financing was realised in form of private bonds with warrants which can be
Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases, is to be sold to Genfit. With this acquisition, Genfit intends to expand its product portfolio
VISCHER has advised Forty51 Ventures, a Biotech venture capital firm, on its first fund, Forty51 Ventures Fund I which has raised USD 43 million in a first closing and is domiciled in Luxemburg. VISCHER has supported,
Mosanna Therapeutics, a Basel-based biotechnology company, has closed a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of the molecule MOS118 and for regulatory activities in
Novaremed, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics, a China-based clinical stage neuroscience biotech company, jointly announced the signing of an exclusive collaboration and commercialization agreement for non-opioid investigational drug, NRD.E1. The
